SCHEMBL29186536

SCHEMBL29186536

COc1cc(Oc2ccnc3ccc(C(N)=O)cc23)cc(-n2cccn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDR2 Q16832 1/20 0.49
▸ MET P08581 5/20 0.47
▸ AXL P30530 1/20 0.47
▸ MERTK Q12866 1/20 0.47
▸ KAT6A Q92794 2/20 0.43
▸ KDR P35968 5/20 0.43
▸ AURKA O14965 3/20 0.43
▸ TEK Q02763 3/20 0.43
▸ AURKB Q96GD4 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ LYN P07948 1/20 0.42
▸ KCNH2 Q12809 2/20 0.41
▸ FGFR2 P21802 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049913 1.00 DDR2 (0.49) DDR2METAXLMERTKKAT6A
SCHEMBL29186530 0.90 MET (0.45) DDR2METAXLMERTKKDR
SCHEMBL30049826 0.90 MET (0.45) DDR2METAXLMERTKKDR
SCHEMBL29317806 0.90 MET (0.47) DDR2METAXLMERTKKAT6A
SCHEMBL30049861 0.90 MET (0.47) DDR2METAXLMERTKKAT6A
SCHEMBL29186571 0.90 DDR2 (0.52) DDR2METAXLMERTKKAT6A
SCHEMBL30050923 0.89 MET (0.47) DDR2METAXLMERTKKDR
SCHEMBL29317810 0.89 MET (0.47) DDR2METAXLMERTKKDR
SCHEMBL29186539 0.89 MET (0.50) DDR2METAXLMERTKKAT6A
SCHEMBL30050388 0.89 MET (0.50) DDR2METAXLMERTKKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
CN-117321036-A phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity 成都安泰康赛生物科技有限公司 2023-12-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT DDR2 4341/4885MET 4678/4885AXL 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback